PYXS Pyxis Oncology Forecast, Technical & Fundamental Analysis
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma... Show more
PYXS is expected to report earnings to fall 4.05% to -35 cents per share on August 19
Q2'26
Est.
$-0.35
Q1'26
Est.
$-0.37
Q4'25
Missed
by $0.95
Q3'25
Missed
by $0.01
Q2'25
Beat
by $0.04
The last earnings report on May 14 showed earnings per share of -37 cents, meeting the estimate of -37 cents. With 546.28K shares outstanding, the current market capitalization sits at 154.59M.
A.I.dvisor indicates that over the last year, PYXS has been loosely correlated with BLRX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if PYXS jumps, then BLRX could also see price increases.
Momentum Indicator for PYXS turns positive, indicating new upward trend
PYXS saw its Momentum Indicator move above the 0 level on June 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned positive. In of the 75 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PYXS just turned positive on June 17, 2026. Looking at past instances where PYXS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
PYXS moved above its 50-day moving average on June 17, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PYXS crossed bullishly above the 50-day moving average on June 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where PYXS advanced for three days, in of 241 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for PYXS moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where PYXS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PYXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PYXS broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PYXS entered a downward trend on June 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PYXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.943) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). PYXS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (11.050) is also within normal values, averaging (434.181).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PYXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
